Heart Failure (HF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Heart Failure (HF) Marketed and Pipeline Drugs Market Report Overview
Heart Failure (HF) is a critical clinical condition where certain structural and functional abnormalities in the heart impair its ability to meet systemic circulation. The various causes that contribute to these abnormalities are hypertension, arrythmia, valvular heart disease, and risk factors including high cholesterol, infection, and genetic factors.
The Heart Failure (HF) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, mid-to-late-stage pipeline products with phase transition success rate (PTSR), and likelihood of approval (LoA) for heart failure (HF).
Heart Failure Marketed Drugs Segmentation by Mechanisms of Action
The key mechanisms of action for Heart Failure marketed drugs are enzyme inhibitor, receptor antagonist, transporter inhibitor, enzyme activator, ion channel blocker, receptor agonist, ion channel activator, biological factor activator, and protein and peptide activator. The market is dominated by enzyme inhibitor.
Heart Failure Marketed Drugs Analysis, by Mechanisms of Action, 2023 (%)
For more MoA insights into the Heart Failure marketed drugs market, download a free report sample
Heart Failure Marketed Drugs Segmentation by Molecule Type
The key molecule types for Heart Failure marketed drugs are small molecule and biologic. The pipeline market is dominated by small molecule.
Heart Failure Marketed Drugs Analysis, by Molecule Type, 2023 (%)
For more molecule type insights into the Heart Failure marketed drugs market, download a free report sample
Heart Failure Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for Heart Failure marketed drugs are injection, oral, topical, and inhalational. The majority of marketed drugs for HF are oral therapies, followed by injectables.
Heart Failure Marketed Drugs Analysis, by Routes of Administration, 2023 (%)
For more RoA insights into the Heart Failure marketed drugs market, download a free report sample
Heart Failure Pipeline Drugs Segmentation by Mechanisms of Action
Some of the key mechanisms of action for Heart Failure pipeline drugs are enzyme inhibitor, receptor agonist, enzyme activator, receptor antagonist, transporter inhibitor, biological factor activator, protein and peptide activator, and ion channel blocker. The market is dominated by enzyme inhibitor.
Heart Failure Pipeline Drugs Analysis, by Mechanisms of Action, 2023 (%)
For more MoA insights into the Heart Failure pipeline drugs market, download a free report sample
Heart Failure Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for Heart Failure pipeline drugs are injection, oral, topical, and inhalational. Of all the pipeline drugs for HF, the majority use an injection for their route of administration, followed by oral administration.
Heart Failure Pipeline Drugs Analysis, by Routes of Administration, 2023 (%)
For more RoA insights into the Heart Failure pipeline drugs market, download a free report sample
Heart Failure Pipeline Drugs Segmentation by Molecule Type
The key molecule types for Heart Failure pipeline drugs are small molecule, biologic, oligonucleotide, and polymer. Majority of the Heart Failure pipeline drugs are small molecules, followed by biologics.
Heart Failure Pipeline Drugs Analysis, by Molecule Types, 2023 (%)
For more molecule type insights into the Heart Failure pipeline drugs market, download a free report sample
Top Sponsors in the Heart Failure Marketed and Pipeline Drugs Market
Some of the top sponsors in the Heart Failure marketed and pipeline drugs market are Novartis AG, AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co, Mayo Clinic, Virginia Commonwealth University, University of Pennsylvania, Yale University, Otsuka Holdings Co Ltd, and Duke University.
Heart Failure Marketed Drugs Market Report Overview
Key Mechanisms of Action | Enzyme Inhibitor, Receptor Antagonist, Transporter Inhibitor, Enzyme Activator, Ion Channel Blocker, Receptor Agonist, Ion Channel Activator, Biological Factor Activator, and Protein and Peptide Activator |
Key Molecule Types | Small Molecule and Biologic |
Key Routes of Administration | Injection, Oral, Topical, and Inhalational |
Heart Failure Pipeline Drugs Market Report Overview
Key Mechanisms of Action | Enzyme Inhibitor, Receptor Agonist, Enzyme Activator, Receptor Antagonist, Transporter Inhibitor, Biological Factor Activator, Protein and Peptide Activator, and Ion Channel Blocker |
Key Routes of Administration | Injection, Oral, Topical, and Inhalational |
Key Molecule Types | Small Molecule, Biologic, Oligonucleotide, and Polymer |
Top Sponsors (Marketed and Pipeline Drugs) | Novartis AG, AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co, Mayo Clinic, Virginia Commonwealth University, University of Pennsylvania, Yale University, Otsuka Holdings Co Ltd, and Duke University |
Segments Covered in the Report
Heart Failure Marketed Drugs Market Mechanisms of Action Outlook (Number of Products)
- Enzyme Inhibitor
- Receptor Antagonist
- Transporter Inhibitor
- Enzyme Activator
- Ion Channel Blocker
- Receptor Agonist
- Ion Channel Activator
- Biological Factor Activator
- Protein and Peptide Activator
Heart Failure Marketed Drugs Market Molecule Types Outlook (Number of Products)
- Small Molecule
- Biologic
Heart Failure Marketed Drugs Market Routes of Administration Outlook (Number of Products)
- Injection
- Oral
- Topical
- Inhalational
Heart Failure Pipeline Drugs Market Mechanisms of Action Outlook (Number of Products)
- Enzyme Inhibitor
- Receptor Agonist
- Enzyme Activator
- Receptor Antagonist
- Transporter Inhibitor
- Biological Factor Activator
- Protein and Peptide Activator
- Ion Channel Blocker
Heart Failure Pipeline Drugs Market Routes of Administration Outlook (Number of Products)
- Injection
- Oral
- Topical
- Inhalational
Heart Failure Pipeline Drugs Market Molecule Types Outlook (Number of Products)
- Small Molecule
- Biologic
- Oligonucleotide
- Polymer
Scope
GlobalData’s Heart Failure (HF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the HF market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HF market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for Heart Failure pipeline drugs?
The key mechanisms of action in the Heart Failure pipeline drugs market are enzyme inhibitor, receptor agonist, enzyme activator, receptor antagonist, transporter inhibitor, biological factor activator, protein and peptide activator, and ion channel blocker.
-
What are the key routes of administration for Heart Failure pipeline drugs?
The key routes of administration in the Heart Failure pipeline drugs market are injection, oral, topical, and inhalational.
-
What are the key molecule types for Heart Failure pipeline drugs?
The key molecule types in the Heart Failure pipeline drugs market are small molecule, biologic, oligonucleotide, and polymer.
-
Who are the top sponsors for Heart Failuremarketed and pipeline drugs market?
Some of the top sponsors for the Heart Failure marketed and pipeline drugs market are Novartis AG, AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co, Mayo Clinic, Virginia Commonwealth University, University of Pennsylvania, Yale University, Otsuka Holdings Co Ltd, and Duke University.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.